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Abstract
This cross-sectional observational study measured symptoms of pelvic floor disorders (PFDs) and their effect
on quality of life in 25 women returning for postoperative care at least 6 months after total abdominal
hysterectomy for endometrial cancer. Pelvic floor symptoms and impact were assessed using the short-form
versions of 2 validated quality of life questionnaires: the Pelvic Floor Distress Inventory (PFDI-20) and the
Pelvic Floor Impact Questionnaire (PFIQ-7). Pelvic symptoms were reported at a much higher rate (84%) than
in the general public, with a mean “bother” score in the mild range: 26.4 64.5. Although the degree of bother
most commonly was mild, patients should be counseled that these embarrassing symptoms are possible and
potentially screened for after surgical intervention.
Background: The primary goal of this study was to determine the prevalence of pelvic floor symptoms in postoperative
patients with endometrial cancer. The secondary goal was to assess the impact of these issues on patient quality of life.
Methods: This cross-sectional study looked at women (N  25) returning for postoperative care at least 6 months after
total abdominal hysterectomy for endometrial cancer. Demographic and clinical data were collected. Severity of pelvic
floor symptoms was assessed using the short-form version of the Pelvic Floor Distress Inventory (PFDI-20). The impact of
these symptoms on quality of life was assessed using the short-form version of the Pelvic Floor Impact Questionnaire
(PFIQ-7). Demographic data and PFDI-20 and PFIQ-7 scores were summarized using descriptive statistics. Results:
Pelvic symptoms were reported at a much higher rate than seen in the general public. Symptom prevalence was reported
by 21/25 (84%) patients on the PFDI-20 questionnaire, with a mean score of 52.5 64.8. Patients reported prevalence of
symptoms in the following order: urinary symptoms (19/25 [76%])  colorectal-anal symptoms (17/25 [68%])  pelvic
organ prolapse symptoms (11/25 [44%]). Slightly fewer than half (11/24) of the study participants reported quality of life
issues associated with their pelvic symptoms, with a mean score in the mild range: 26.4 64.5. The reported prevalence
of the effect of pelvic symptoms on quality of life was urinary (10/25 [40%])  colorectal-anal (8/24 [33%])  pelvic organ
prolapse (4/24 [17%]). Conclusion: This study has shown that there was a high prevalence of symptoms of PFDs in our
population after abdominal hysterectomy for endometrial cancer.
Clinical Ovarian & Other Gynecologic Cancer, Vol. 5, No. 1, 27-30 © 2012 Elsevier Inc. All rights reserved.
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UIntroduction
Pelvic floor disorders (PFDs) are common and include urinary
incontinence, pelvic organ prolapse, and fecal incontinence. A recent
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28 Cthe general population to be 23.7%, with 15.7% of women experi-
encing urinary incontinence, 2.9% of women experiencing pelvic
organ prolapse, and 9.0% of women experiencing fecal incontinence
symptoms.1 Moreover the proportion of women reporting at least 1
isorder increased incrementally with age, parity, and body mass
ndex (BMI).2 As a result, more than 338,000 procedures for PFD
re performed each year in the United States, with a total cost esti-
ated to be more than $1 billion annually.3,4
Risk factors for prolapse include BMI, older age, higher gravidity
and parity, and history of hysterectomy (especially hysterectomy for
prolapse or other prolapse or incontinence operations).5-7 These are
ome of the same risk factors associated with an increased risk of
ndometrial cancer. This cancer is the most common gynecologic
alignancy in the United States, with 40,100 cases diagnosed and
470 deaths occurring annually. Of those cases, approximately 75%
f patients are diagnosed with stage I cancer, the treatment for which
s hysterectomy  lymph node sampling.8,9
Given the similarities in the risk factors for these 2 disease pro-
cesses and anecdotal evidence at our institution, we hypothesized
that there is a high probability that the 2 conditions may coexist.
However, a MEDLINE search between January 1964 and April
2009, using the terms hysterectomy, endometrial cancer, inconti-
nence, fecal, urinary, prolapse, cystocele, rectocele, uterine, and en-
terocele did not identify any published studies addressing the preva-
lence of PFD symptoms in this patient population. The goal of our
pilot study was to identify the prevalence of symptoms of PFD in
posthysterectomy patients with endometrial cancer within the first 5
postoperative years. In addition, we sought to assess the impact of
these issues on patient quality of life.
Patients and Methods
This was a cross-sectional study of women returning for postop-
erative care at least 6 months after total abdominal hysterectomy for
endometrial cancer. It was approved by the institutional review
board of our metropolitan tertiary referral center. Informed consent
was obtained at the time the survey was distributed. Inclusion criteria
were any patient with the diagnosis of endometrial cancer (made by
surgical or pathologic diagnosis) who underwent a hysterectomy as
part of the treatment. Participants were recruited between April 2008
and June 2009. Exclusion criteria included previous radiation ther-
apy and previous surgery for PFDs.
Demographic data were collected at the time of questionnaire
distribution. These features included age, height and weight, time
since surgery, the 2008 International Federation of Gynecology and
Obstetrics cancer stage, type of hysterectomy, menopausal status,
hormone replacement status, smoking status, parity, and number of
Table 1 Demographic Data in (N  25) Posthysterectomy Pati
Age (Y) BMI (kg/m2) Time SinceOperation (Mo)
C
IA
62 (34-80) 32 (19-46) 22 (6-42) 6 (24%) 14
20 (80%)
Continuous data summarized as mean (range).vaginal deliveries. Two validated questionnaires were used to assess
linical Ovarian & Other Gynecologic Cancer June 2012PFD symptoms and their effect on quality of life.10,11 Severity of
pelvic floor symptoms was assessed using the short-form version of
the Pelvic Floor Distress Inventory (PFDI-20), which is composed
of 3 subscales: Urinary Distress Inventory (UDI-6), Pelvic Organ
Prolapse Distress Inventory (POPDI-6), and Colorectal-Anal Dis-
tress Inventory (CRADI-8).10,11 The impact of these symptoms on
uality of life was assessed using the short-form version of the Pelvic
loor Impact Questionnaire (PFIQ-7). The PFIQ-7 is composed of
scales (Urinary Impact Questionnaire (UIQ), Colorectal-Anal Im-
act Questionnaire (CRAIQ), and the Pelvic Organ Prolapse Impact
uestionnaire (POPIQ)).
The PFDI-20 is a set of 20 symptom questions, answered on a
-point Likert scale: 1 not at all to 4 quite a bit. Themean values
f all answered items aremultiplied by 25 to determine the scale score
range 0-100). A summary score is also reported (range 0-300). The
FIQ-7 is a set of 21 impact question, answered on a similar 4-point
ikert scale. The mean value of all answered items are multiplied by
100/3) to obtain the scale score (range 0-100). Again, a summary score
s also reported (range 0-300). Higher scores denote a greater symptom
r impact score.12 PFDI-20 and PFIQ-7 scores were averaged using
escriptive statistics and compared with historical means.1
Results
A total of 34 patients met the inclusion criteria, and 25 patients
were recruited for the study. Demographic data are summarized in
Table 1. Mean age of participants was 62  12 years and median
ollow-up was 19 months (range, 6-42 months). The predominant
ndometrial cancer stage was IB. All candidates weremenopausal and
ormone naive and had undergone extrafascial abdominal hysterec-
omy with bilateral salpingo-oophorectomy lymph node sampling
19/25). Pelvic symptoms were reported by 21/25 (84%) patients on
he PFDI-20 questionnaire, with a mean score of 52.2 64.8. Mild
ymptoms (PFDI-20 score 1-100) were reported by 19/25 (76%)
nd severe symptoms (PFDI-20 score 200-300) were reported by
/25 (8%) of study participants. Symptom prevalence occurred in
he following order: urinary symptoms (19/25 [76%]) colorectal-
nal symptoms (17/25 [68%])  pelvic organ prolapse symptoms
11/25 [44%]) (Table 2), demonstrating thatmost posthysterectomy
atients with endometrial cancer had more than 1 pelvic floor symp-
om. There was no significant association of pelvic floor symptoms or
oorer quality of life to a higher endometrial cancer stage (P .05).
Slightly fewer than half (11/25 [44%]) of the study participants
eported quality of life issues associated with their pelvic symptoms,
ith a mean score of 26.4 64.5. Nine of the symptoms were in the
mild range (PFIQ-7 score 0%-33%), and 1 symptom each was in the
moderate or severe range. The reported prevalence of the effect of
With Endometrial Cancer
r Stage
Smoker Parity No. of VaginalDeliveriesIC IIA
3 (12%) 2 (8%) 2 (8%) 2 (0-4) 2 (0-4)
5 (20%)ents
ance
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(56%)pelvic symptoms on quality of life was distributed as follows: urinary
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Patrick A. Nosti et al(10/25 [40%])  colorectal-anal (8/24 [33%])  pelvic organ pro-
apse (4/24 [17%]) (Table 3).
Discussion
The PFDI-20 and PFIQ-7 are 2 complimentary condition-specific
health-related quality-of-life questionnaires for women with PFDs.13
The PFDI and PFIQ can be used tomeasure the extent of lower urinary
tract, colorectal-anal, and pelvic organ prolapse symptoms and how they
affect the quality of life of these women. They are validated, reliable, and
responsive to change and have become a common measure of patient-
oriented outcomes in urogynecologic research.10,11,13 They measure
ymptom distress and the impact of those symptoms on daily activity,
elationships, and emotions. These patient-oriented outcomes have
een recommended for improving the quality of clinical research proj-
cts and are strategic goals for the Agency for Healthcare Research and
uality. By linking the care individuals get to the outcomes they expe-
ience, outcomes research has become a key to developing better ways to
onitor and improve quality of care.14
Interestingly, women who underwent hysterectomy for endome-
trial cancer had a much higher rate of symptoms of PFDs (84%)
compared with the historical rate (23.7%) in the general popula-
tion.1 Anecdotally, the wide dissection and lymphadenectomy create
scarring and fibrosis, resulting in less extensive pelvic organ prolapse
than seen in the general hysterectomy population. This dichotomy
persisted even when the populations of these 2 studies were similar
with regard to parity, BMI, and age. In the PFDN study, previous
hysterectomy was not analyzed as a subcategory. Research has shown
that hysterectomy increases the risk of PFDs.6,15-17 In 1 such study,
he cumulative risk of surgery for pelvic organ prolapse rose from 1%
t 3 years after hysterectomy to 5% at 15 years.15
However we also found that there was a poor correlation between
Table 2 Study Responses for Pelvic Floor Distress Inventory—
Patient Category (%) POPDI-6a (N  25) CRADI
Mild (1-33) 8
Moderate (34-66) 1
Severe (67-100) 2
Absent 14
Mean Score 11.3  22.8 15
Abbreviations: CRADI-8 Colorectal-Anal Distress Inventory; PFDI-20 Pelvic Floor Distress
a Patients stratified into mild, moderate, and severe categories based on total points out of 100 for
Table 3 Study Responses for Pelvic Floor Impact Questionnair
Patient Categorya (%) POPIQ (n  24) CRA
Mild (1-33) 2
Moderate (34-66) 1
Severe (67-100) 1
Absent 20
Mean Score 7.5  24.0 8
Abbreviations: CRAIQ Colorectal-Anal Impact Questionnaire; PFIQ-7 Pelvic Floor Impact Que
a Patients stratified into mild, moderate, and severe categories based on total points out of 100symptomatic PFD and quality of life measures. Slightly less than halfof the study population reported quality of life “bother” associated
with their pelvic symptoms. In those with any PFD symptoms, most
were in the mild range. Of note, although symptomatic pelvic floor
distress has been correlated with quality of life measures, the associ-
ation is typically observed in women with more severe symp-
toms.18,19 PFDs were not associated with a higher endometrial can-
cer stage.
This preliminary study has some limitations. First, our sample size
was small (N 25) and lacked baseline preoperative data. This was
because of the practice patterns at our tertiary referral institution.
Patients with stage I disease were often directed back to their general
obstetrician/gynecologist for follow-up visits after the initial postop-
erative period had passed. This prohibited the collection of question-
naires from these patients and also introduced a level of selection bias
to our study. A larger population could undergomultivariate analysis to
determinemajor risk factors forPFDs inpostoperativewomenwhohave
undergone hysterectomy for endometrial cancer. Patients with more
aggressive or advanced-stage tumors were more likely to follow up with
their oncologist. If these patients had more aggressive or invasive proce-
dures, theymay be prone tomore PFDs. Could it be that excision of the
parametrium removes the elastofibromuscular support tissue typically
used for resuspension of the resultant vaginal cuff? Patients with postop-
erative problems, such as PFD symptoms, may be more likely to return
to their operating surgeon as opposed to their local generalist. Such an
effect would have artificially increased the rate of PFD symptoms re-
ported in the present study. One last consideration is the medium-term
follow-up: If these patients are again surveyed after 5 or 10 years, the
prevalence of PFD symptoms or subjective distress may have dropped,
although this would not be expected to drop below baseline levels.
However the findings of this study underscore the importance of
t Form 20
 25) UDI-6a (N  25) PFDI-20a (N  25)
13 19
4 0
2 2
6 4
0.6 25.5  27.7 52.2  64.8
ry; POPDI-6 Pelvic Organ Prolapse Distress Inventory; UDI-6 Urinary Distress Inventory.
ction (ie, POPDI-6, CRADI-8, and UDI-6) and out of 300 for the cumulative score on the PFDI-20.
ort Form 7
 24) UIQ (n  25) PFIQ-7 (n  24)
8 9
1 1
1 1
15 13
9.5 10.1  21.9 26.4  64.5
ire; POPIQ Pelvic Organ Prolapse Impact Questionnaire; UIQ Urinary Impact Questionnaire.
h section (ie, UIQ, CRAIQ, POPIQ) and out of 300 for the cumulative score on the PFIQ-7.Shor
-8a (N
14
1
2
8
.4  2e—Sh
IQ (n
6
1
1
16
.3  1research in this population. Future investigations would benefit from
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30 Cthe identification of patients with PFDs preoperatively. This would
establish a PFD symptom baseline for these patients. In addition,
follow-up through mailed surveys would decrease the number of
patients lost to follow-up and thus increase the total number of study
participants. If the prevalence of PFD symptoms in patients with
endometrial cancer is higher, these patients may benefit from con-
sultation before surgery, concomitant procedures when indicated,
and increased clinical screening postoperatively.
Conclusion
This study has shown that there was a high prevalence of PFD
symptoms in our population of women who underwent abdominal
hysterectomy for endometrial cancer. A large prospective cohort
study is necessary to verify these results. Although the degree of
bother most commonly was mild, patients should be counseled that
these symptoms are possible. Early screening of this high-risk popu-
lation in the postoperative period may increase identification and
improve patient quality of life.
Clinical Practice Points
● There is a high prevalence of symptoms of PFD after hysterectomy
for endometrial cancer.
● Most women have symptoms of pelvic floor disorder in more than
1 organ system, eg, urinary incontinence, pelvic prolapse, or colo-
rectal-anal issues.
● The negative quality of life effects in most women who have had
hysterectomy for endometrial cancer are in the mild range.
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